Track topics on Twitter Track topics that are important to you
The purpose of this study is to assess the comparative safety and effectiveness of Aztreonam for Inhalation Solution versus Tobramycin Nebuliser Solution in adult and pediatric patients with CF and pulmonary Pseudomonas aeruginosa (PA) infection.
Number of Subjects Planned: Approximately 200 randomized patients
Target Population: CF patients >/= 6 years of age with stable pulmonary disease, who at study entry have a recent positive sputum culture for PA and have been previously treated with aerosolized antibiotics without demonstration of drug intolerance.
Study Design: This is an open-label, multicenter, randomized, parallel group study. The study design consists of two treatment arms of 28-day, intermittent, repeating treatment regimens: Aztreonam for Inhalation Solution (AZLI) or Tobramycin Inhalation Solution (TIS). The total study period will be 26 weeks. The study schedule will include nine visits - Screening, Baseline, Day 14, Day 28, then visits every 28 days through the end of the study.
Study Design: This is an open-label, multicenter, randomized, parallel group study. The study design consists of two treatment arms of 28-day, intermittent, repeating treatment regimens: Aztreonam 75 mg Powder and Diluent for Nebulizer Solution (AZLI) or Tobramycin Nebuliser Solution (TNS). The total study period will be 26 weeks. The study schedule will include nine visits - Screening, Baseline, Day 14, Day 28, then visits every 28 days through the end of the study.
An open-label, single-arm extension is available for subjects who have completed at least one course of AZLI or TNS during the randomized portion of the study. Subjects may be eligible to receive three additional cycles of AZLI in a 28-day, intermittent, repeating treatment regimen.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Aztreonam for Inhalation Solution, Tobramycin Nebuliser Solution
Published on BioPortfolio: 2014-07-23T21:20:14-0400
The purpose of this research study is to see if an experimental drug called Aztreonam for Inhalation Solution is safe and effective to treat Burkholderia lung infections in patients with C...
The purpose of this research study is to determine if multiple doses of two inhaled drugs will help Cystic Fibrosis patients whose lungs are infected with a bacteria called Burkholderia do...
This study compares the safety of the tobramycin solution for inhalation with the tobramycin dry powder formulation, used with a simple inhaler
The aim of this study is to investigate the efficacy of antibiotic therapy with any antibiotic (IV) and IV (Nebcin®) tobramycin for 5 days followed by Solution for nebuliser inhalation (T...
The purpose of this study is to evaluate tobramycin inhalation solution (TIS) once daily compared tot placebo, and open label twice daily, in patients with non-CF bronchiectasis. The prima...
Pseudomonas aeruginosa is a major pathogen of the chronic lung infections in cystic fibrosis (CF) patients. These persistent bacterial infections are characterized by bacterial aggregates with biofilm...
CF pulmonary guidelines recommend alternate therapy (one month on, one month off) with inhaled tobramycin for chronic Pseudomonas aeruginosa colonization in cystic fibrosis (CF). Tobramycin-inhaled po...
Viral infections contribute to morbidity in cystic fibrosis (CF), but the impact of respiratory viruses on the development of airway disease is poorly understood.
s Tobramycin (TOB) and clarithromycin (CLA) can potentially be used synergistically for the treatment of respiratory infections caused by Pseudomonas aeruginosa (P. aeruginosa) in cystic fibrosis (CF)...
Hypertonic sodium chloride solution. A solution having an osmotic pressure greater than that of physiologic salt solution (0.9 g NaCl in 100 ml purified water).
The pressure required to prevent the passage of solvent through a semipermeable membrane that separates a pure solvent from a solution of the solvent and solute or that separates different concentrations of a solution. It is proportional to the osmolality of the solution.
An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.
A chloride channel that regulates secretion in many exocrine tissues. Abnormalities in the CFTR gene have been shown to cause cystic fibrosis. (Hum Genet 1994;93(4):364-8)
Solution that is usually 10 percent glucose but may be higher. An isotonic solution of glucose is 5 percent.
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza, Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...